Advances in neoadjuvant therapy for colorectal cancer with liver metastases

Cancer Treatment Reviews

Volumn 34, Issue 4, 2008, Pages 293-301

  Pozzo, Carmelo ^a   Barone, Carlo ^a   Kemeny, Nancy E ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Irinotecan; Oxaliplatin; Resection

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DEXAMETHASONE; EPIRUBICIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLACEBO;

ADD ON THERAPY; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER SIZE; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG ACTIVITY; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PREOPERATIVE TREATMENT; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FLUOROURACIL; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS;

EID: 43949083039     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.01.004     Document Type: Review

References (62)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. American Cancer Society. Cancer Facts & Figures 2007 (2007), Atlanta, American Cancer Society
3. Kemeny N. Management of liver metastases from colorectal cancer. Oncology 20 (2006) 1161-1176
4. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 14 Suppl. 2 (2003) ii13-ii16
5. Wood C.B., Gillis C.R., and Blumgart L.H. A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 2 (1976) 285-288
6. Wagner J.S., Adson M.A., Van Heerden J.A., Adson M.H., and Ilstrup D.M. The natural history of hepatic metastases from colorectal cancer: a comparison with resective treatment. Ann Surg 199 (1984) 502-507
7. Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin 49 (1999) 231-255
8. Mayer R.J. Moving beyond fluorouracil for colorectal cancer. N Engl J Med 343 (2000) 963-964
9. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343 (2000) 905-914
10. Douillard J.-Y. Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer. Oncology (Williston Park) 14 Suppl. 14 (2000) 51-55
11. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
12. Giacchetti S., Perpoint B., Zidani R., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18 (2000) 136-147
13. Goldberg R.M., Rothenberg M.L., Van Cutsem E., et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 12 (2007) 38-50
14. Grothey A., Sargent D., Goldberg R.M., and Schmoll H.-J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22 (2004) 1209-1214
15. Seymour M.T., Maughan T.S., Ledermann J.A., and for the FOCUS Trial Investigators and the National Cancer Institute Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370 (2007) 143-152
16. Koopman M., Antonini N.F., Douma J., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370 (2007) 135-142
17. Tournigand C., André C., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004) 229-237
18. Kemeny N.E., Niedzwiecki D., Hollis D.R., et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALBG 9481). J Clin Oncol 24 (2006) 1395-1403
19. Kemeny N., Gonen M., Sullivan D., et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 19 (2001) 2687-2695
20. Kemeny N., Jarnagin W., Paty P., et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 23 (2005) 4888-4896
21. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
22. Hurwitz H.I., Fehrenbacher L., Hainsworth J.D., et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23 (2005) 3502-3508
23. Fuchs C.S., Marshall J., Mitchell E., et al. Randomized, controlled trial of irinotecan plus infusionnoal, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 25 (2007) 4779-4786
24. Hochster H.S., Hart L.L., Ramanathan R.K., Hainsworth J.D., Hedrick E.E., and Childs B.H. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-study. J Clin Oncol 24 Suppl. 18S (2006) Abstract 3510
25. Saltz L., Clarke S., Diaz-Rubio E., et al. Bevacizumab (BEV) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). J Clin Oncol 25 Suppl. 18S (2007) Abstract 4028
26. Van Cutsem E., Nowacki M., Lang I., et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol 25 Suppl. 18S (2007) Abstract 4000
27. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. Oral presentation at: 43rd American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 1-5, 2007.
28. Malavasi N., Dealis C., Depenni R., et al. Phase II trial to evaluate combination of folfox6 + bevacizumab in initially unresectable liver metastases from colorectal cancer (crc). J Clin Oncol 25 Suppl 18S (2007) Abstract 14603
29. Amgen discontinues Vectibix (TM) treatment in PACCE trial evaluating Vectibix(TM) as part of triple combination regimen [news release]. Thousand Oaks, CA: Amgen Inc; March 22, 2007. http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2007&releaseID=977186. [accessed 01.02.08].
30. Cunningham D., Allum W.H., Stenning S.P., et al., for the MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 (2006) 11-20
31. Nordlinger B., Sorbye H., Collette L., et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol 25 Suppl. 18 (2007) LBA5
32. Kemeny N.E., Capanu M., Huitzil-Melendez F., et al. Is neoadjuvant (neoadj) treatment necessary prior to liver resection in patients with resectable liver metastases (mets) from colorectal carcinoma (CRC) treated with post-resection hepatic arterial infusion (HAI) plus systemic (SYS) chemotherapy?. J Clin Oncol 25 Suppl. 18 (2007) 14503
33. Jatzko G.R., Lisborg P.H., Stettner H.M., and Klimpfinger M.H. Hepatic resection for metastases from colorectal carcinoma-a survival analysis. Eur J Cancer 31A (1995) 41-46
34. Chiappa A., Zbar A.P., Biella F., and Staudacher C. Survival after repeat hepatic resection for recurrent colorectal metastases. Hepatogastroenterology 46 (1999) 1065-1070
35. Pozzo C., Basso M., Cassano A., et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 15 (2004) 933-939
36. Van Cutsem E., Nordlinger B., Adam R., et al., on behalf of European Colorectal Metastases. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 42 (2006) 2212-2221
37. Folprecht G., Grothey A., Alberts S., Raab H.-R., and Köhne C.-H. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16 (2005) 1311-1319
38. Adam R., Avisar E., Ariche A., et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann Surg Oncol 8 (2001) 347-353
39. Giacchetti S., Itzhaki M., Gruia G., et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10 (1999) 663-669
40. Delaunoit T., Alberts S.R., Sargent D.J., et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 16 (2005) 425-429
41. Zelek L., Bugat R., Cherqui D., et al., on behalf of the European Association for Research in Oncology. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol 14 (2003) 1537-1542
42. Barone C., Nuzzo G., Cassano A., et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 97 (2007) 1035-1039
43. Alberts S.R., Horvath W.L., Sternfeld W.C., et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 23 (2005) 9243-9249
44. Aloia T., Levi F., Wicherts D.A., et al. Hepatic resection following rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25 Suppl. 18S (2007) Abstract 4061
45. Nordlinger B, Sorbye H, Collette L, et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. Oral presentation at: 43rd American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 1-5, 2007.
46. Pozzo C., Basso M., Quirino M., et al. Long-term follow-up of colorectal cancer (CRC) patients treated with neoadjuvant chemotherapy with irinotecan and fluorouracil plus folinic acid (5-FU/FA) for unresectable liver metastases. J Clin Oncol 24 Suppl. 18 (2006) Abstract 3576
47. Ho W.M., Mok T.S., Ma B.B., et al., for the Cancer Therapeutic Research Group. Liver resection after irinotecan (CPT-11), 5-fluorouracil (5FU) and folinic acid (FA) for patients (pts) with unresectable liver metastases (Mets) from colorectal cancer (CRC). J Clin Oncol 22 Suppl. (2003) Abstract 1253
48. De La Cámara J., Rodriguez J., Rotellar F., et al. Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. J Clin Oncol 22 Suppl. 14S (2004) Abstract 3593
49. Quenet F., Nordlinger B., Rivoire M., et al. Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): a prospective phase II trial. J Clin Oncol 22 Suppl. 14S (2004) Abstract 3613
50. Khatri V.P., Petrelli N.J., and Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit?. J Clin Oncol 23 (2005) 8490-8499
51. Chiche L., and for the Agence nationale d'accréditation et d'évaluation en santé (ANAES). When is first-line resection of hepatic metastasis indicated? Recommendations for clinical practice: therapeutic management of hepatic metastases in colorectal cancers [clinical practice guideline] [in French]. Gastroenterol Clin Biol 27 (2003) B41-B61
52. Poston G., Adam R., and Vauthey J.-N. Downstaging or downsizing: time for a new staging system in advanced colorectal cancer?. J Clin Oncol 24 (2006) 2702-2706
53. Poston G.J., Adam R., Alberts S., et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 23 (2005) 7125-7134
54. Capussotti L., Viganò L., Ferrero A., Lo Tesoriere R., Ribero D., and Polastri R. Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis-based decisional model. Ann Surg Oncol 14 (2007) 1143-1150
55. Capussotti L., Ferrero A., Viganò L., Ribero D., Lo Tesoriere R., and Polastri R. Major liver resections synchronous with colorectal surgery. Ann Surg Oncol 14 (2007) 195-201
56. Muratore A., Zorzi D., Bouzari H., et al. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?. Ann Surg Oncol 14 (2007) 766-770
57. Adam R., Pascal G., Castaing D., et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?. Ann Surg 240 (2004) 1052-1061 discussion 1061-4
58. King P.D., and Perry M.C. Hepatotoxicity of chemotherapy. Oncologist 6 (2001) 162-176
59. Fernandez F.G., Ritter J., Goodwin J.W., Linehan D.C., Hawkins W.G., and Strasberg S.M. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200 (2005) 845-853
60. Eloxatin [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; 2006.
61. Rubbia-Brandt L., Audard V., Sartoretti P., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15 (2004) 460-466
62. Adam R., Sebagh M., Plasse M., et al. Impact of preoperative systemic chemotherapy on liver histology and outcome of hepatic resection for colorectal cancer liver metastases (CRLM). J Clin Oncol 23 Suppl. 16S (2005) Abstract 3529